Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC Jr, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD.
Yardley DA, et al. Among authors: debusk lm.
Breast Cancer Res Treat. 2020 Apr;180(3):647-655. doi: 10.1007/s10549-020-05563-z. Epub 2020 Feb 14.
Breast Cancer Res Treat. 2020.
PMID: 32060783
Clinical Trial.